$80,000 of JOHNSON & JOHNSON SERVICES INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Issues related to civil justice reform, including third party litigation funding reform Trade and tariffs affecting the pharmaceutical industry"
You can find more data on corporate lobbying on Quiver Quantitative.
JNJ Congressional Stock Trading
Members of Congress have traded $JNJ stock 14 times in the past 6 months. Of those trades, 4 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by members of Congress over the last 6 months:
- REPRESENTATIVE THOMAS H. KEAN, JR. has traded it 3 times. They made 0 purchases and 3 sales worth up to $115,000 on 03/26, 01/23, 11/20.
- REPRESENTATIVE RICHARD MCCORMICK has traded it 3 times. They made 1 purchase worth up to $15,000 on 11/05 and 2 sales worth up to $30,000 on 03/19.
- SENATOR JOHN BOOZMAN sold up to $15,000 on 03/19.
- REPRESENTATIVE LLOYD DOGGETT has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/10, 12/09 and 0 sales.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
JNJ Insider Trading Activity
JNJ insiders have traded $JNJ stock on the open market 18 times in the past 6 months. Of those trades, 1 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by insiders over the last 6 months:
- JOAQUIN DUATO (CEO and Chairman of the Board) has made 0 purchases and 2 sales selling 100,000 shares for an estimated $22,122,893.
- JOSEPH J WOLK (Exec VP, CFO) has made 0 purchases and 4 sales selling 89,654 shares for an estimated $21,767,826.
- JAMES D. SWANSON (EVP, CIO) has made 0 purchases and 3 sales selling 62,080 shares for an estimated $15,109,758.
- JOHN C REED (EVP, Innovative Medicine, R&D) has made 0 purchases and 3 sales selling 53,931 shares for an estimated $13,105,233.
- TIMOTHY SCHMID (EVP, WW Chair, MedTech) has made 0 purchases and 3 sales selling 23,945 shares for an estimated $5,852,268.
- VANESSA BROADHURST (EVP, Global Corp Affairs) sold 6,197 shares for an estimated $1,508,287
- ROBERT J DECKER (VP Corporate Controller) sold 4,075 shares for an estimated $1,010,070
- JOHN G MORIKIS purchased 1,250 shares for an estimated $257,687
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
JNJ Hedge Fund Activity
We have seen 1,815 institutional investors add shares of JNJ stock to their portfolio, and 2,103 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AUTO-OWNERS INSURANCE CO removed 69,083,868 shares (-99.5%) from their portfolio in Q1 2026, for an estimated $16,851,282,501
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 46,320,499 shares (-72.8%) from their portfolio in Q4 2025, for an estimated $9,586,027,268
- CAPITAL WORLD INVESTORS added 9,692,884 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,005,942,343
- FRANKLIN RESOURCES INC removed 5,342,443 shares (-33.1%) from their portfolio in Q4 2025, for an estimated $1,105,618,578
- FMR LLC added 5,333,244 shares (+39.7%) to their portfolio in Q4 2025, for an estimated $1,103,714,845
- VANGUARD GROUP INC added 3,731,074 shares (+1.6%) to their portfolio in Q4 2025, for an estimated $772,145,764
- PRICE T ROWE ASSOCIATES INC /MD/ added 3,655,754 shares (+41.7%) to their portfolio in Q4 2025, for an estimated $756,558,290
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
JNJ Analyst Ratings
Wall Street analysts have issued reports on $JNJ in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 01/28/2026
- TD Cowen issued a "Buy" rating on 01/22/2026
- Goldman Sachs issued a "Buy" rating on 12/19/2025
- Guggenheim issued a "Buy" rating on 12/05/2025
To track analyst ratings and price targets for JNJ, check out Quiver Quantitative's $JNJ forecast page.
JNJ Price Targets
Multiple analysts have issued price targets for $JNJ recently. We have seen 16 analysts offer price targets for $JNJ in the last 6 months, with a median target of $250.0.
Here are some recent targets:
- Larry Biegelsen from Wells Fargo set a target price of $263.0 on 04/15/2026
- Rick Wise from Stifel set a target price of $250.0 on 04/15/2026
- Matt Miksic from Barclays set a target price of $255.0 on 04/15/2026
- Terence Flynn from Morgan Stanley set a target price of $267.0 on 04/10/2026
- Michael Nedelcovych from TD Cowen set a target price of $250.0 on 04/08/2026
- Shagun Singh from RBC Capital set a target price of $255.0 on 03/30/2026
- Morten Herholdt from HSBC set a target price of $280.0 on 03/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
